- | OncoCyte
After Final Medicare LCD from Palmetto GBA, OncoCyte Pursues Private Coverage for NSCLC Stratification Test
Molecular diagnostics developer OncoCyte said it will step up its pursuit of coverage by private insurers for its DetermaRx™ non-small cell lung cancer (NSCLC) test, after receiving a final local coverage determination (LCD) from Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS).
- | Ziopharm Oncology
ASCO: Ziopharm’s IL-12 gene therapy boosts survival in hard-to-treat brain cancer
Radiation, chemotherapy and surgery don’t cut it against glioblastoma, an aggressive type of brain cancer that often recurs with a vengeance. Ziopharm is working on a “remote-controlled” gene therapy to buy these patients more time—and early data show it extended patients’ lives by more than a year.
- | Valneva
Covid-19 vaccine being produced in West Lothian plant
Work is already underway at Valneva’s plant in Livingston on the unique Covid-19 inactivated vaccine.
- | Celyad
Developing next-generation CAR T cell therapies to bridge the gap in personalised medicine
Filippo Petti, Chief Executive Officer at Celyad, delves into the disruptive potential of CAR T therapies in treating cancer, and explores the challenges that have held the technology back thus far.
- | Heat Biologics
A Conversation on Vaccine Hesitancy in COVID-19 Times
Significant efforts are underway to develop a vaccine against SARS-CoV-2, the virus that has caused the COVID-19 global pandemic. A critical factor of consideration is the potential impact that vaccine hesitancy could have on these efforts.
- | ProQR
Why Listening to Patient Organizations is Key in Drug Development
As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well. While patient organizations took a backseat in the past, they are continuously gaining importance in drug development today. Nowadays, talking with patient organizations has become paramount for successful drug development, especially in the rare disease space.
- | Cidara Therapeutics
Antifungal and Antiviral Conjugates Platforms Fighting Infectious Diseases with Jeff Stein Cidara Therapeutics
Jeff Stein, President and CEO, Cidara Therapeutics talks about their antifungal platform rezafungin now in Phase 3 clinical development to address the needs of the vulnerable population of patients hospitalized for something else who get a life-threatening fungal infection in the hospital. Jeff also explains their Cloudbreak Antiviral Conjugates platform that is being used to target influenza and COVID-19. Cidara is not developing vaccines or monoclonal antibodies rather long-acting drugs that are virucidal and that recruit the immune system to clean up the infection. He also clearly describes the differences between fungi and viruses.
- | Orchestra BioMed
How Can Early-Stage Medical Device Companies Survive Market Turmoil?
David Hochman, founder and CEO of Orchestra BioMed, shares how the company’s risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic.
